Atlas Trials

Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease

Clinical trial NCT00520767 · COMPLETED

Trial details

NCT number
NCT00520767
Sponsor
Barbara Ann Karmanos Cancer Institute
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Primary Systemic AmyloidosisLight Chain Deposition Disease
Start date
2007-09-01
Primary completion
2010-10-01
Enrollment
35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.